190 related articles for article (PubMed ID: 29027131)
1. Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.
Nicholls SJ; Ray KK; Johansson JO; Gordon A; Sweeney M; Halliday C; Kulikowski E; Wong N; Kim SW; Schwartz GG
Am J Cardiovasc Drugs; 2018 Apr; 18(2):109-115. PubMed ID: 29027131
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.
Shishikura D; Kataoka Y; Honda S; Takata K; Kim SW; Andrews J; Psaltis PJ; Sweeney M; Kulikowski E; Johansson J; Wong NCW; Nicholls SJ
Am J Cardiovasc Drugs; 2019 Feb; 19(1):49-57. PubMed ID: 30155718
[TBL] [Abstract][Full Text] [Related]
3. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
Toth PP; Schwartz GG; Nicholls SJ; Khan A; Szarek M; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Lebioda K; Wong NCW; Sweeney M; Ray KK;
Am J Prev Cardiol; 2022 Sep; 11():100372. PubMed ID: 36039183
[TBL] [Abstract][Full Text] [Related]
4. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Ray KK; Nicholls SJ; Ginsberg HD; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Cummings JL; Sweeney M; Schwartz GG
Am Heart J; 2019 Nov; 217():72-83. PubMed ID: 31520897
[TBL] [Abstract][Full Text] [Related]
5. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.
Ray KK; Nicholls SJ; Buhr KA; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Sweeney M; Schwartz GG;
JAMA; 2020 Apr; 323(16):1565-1573. PubMed ID: 32219359
[TBL] [Abstract][Full Text] [Related]
6. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.
Haarhaus M; Ray KK; Nicholls SJ; Schwartz GG; Kulikowski E; Johansson JO; Sweeney M; Halliday C; Lebioda K; Wong N; Brandenburg V; Beddhu S; Tonelli M; Zoccali C; Kalantar-Zadeh K
Atherosclerosis; 2019 Nov; 290():59-65. PubMed ID: 31568963
[TBL] [Abstract][Full Text] [Related]
7. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study.
Nicholls SJ; Schwartz GG; Buhr KA; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Toth PP; Wong N; Sweeney M; Ray KK;
Cardiovasc Diabetol; 2021 Jan; 20(1):13. PubMed ID: 33413345
[TBL] [Abstract][Full Text] [Related]
8. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.
Nicholls SJ; Puri R; Wolski K; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJ; Hu B; Uno K; Kataoka Y; Herrman JP; Merkely B; Borgman M; Nissen SE
Am J Cardiovasc Drugs; 2016 Feb; 16(1):55-65. PubMed ID: 26385396
[TBL] [Abstract][Full Text] [Related]
9. Apabetalone - BET protein inhibition in cardiovascular disease and Type 2 diabetes.
Brandts J; Ray KK
Future Cardiol; 2020 Sep; 16(5):385-395. PubMed ID: 32378426
[TBL] [Abstract][Full Text] [Related]
10. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
Tsujikawa LM; Fu L; Das S; Halliday C; Rakai BD; Stotz SC; Sarsons CD; Gilham D; Daze E; Wasiak S; Studer D; Rinker KD; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Clin Epigenetics; 2019 Jul; 11(1):102. PubMed ID: 31300040
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
12. BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes.
Wasiak S; Dzobo KE; Rakai BD; Kaiser Y; Versloot M; Bahjat M; Stotz SC; Fu L; Sweeney M; Johansson JO; Wong NCW; Stroes ESG; Kroon J; Kulikowski E
Clin Epigenetics; 2020 Nov; 12(1):166. PubMed ID: 33172487
[TBL] [Abstract][Full Text] [Related]
13. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
[TBL] [Abstract][Full Text] [Related]
14. The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation.
Zhang XX; Lin J; Liang TZ; Duan H; Tan XH; Xi BM; Li L; Liu SW
Acta Pharmacol Sin; 2019 Jan; 40(1):98-110. PubMed ID: 29789664
[TBL] [Abstract][Full Text] [Related]
15. Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease.
Kulikowski E; Halliday C; Johansson J; Sweeney M; Lebioda K; Wong N; Haarhaus M; Brandenburg V; Beddhu S; Tonelli M; Zoccali C; Kalantar-Zadeh K
Kidney Blood Press Res; 2018; 43(2):449-457. PubMed ID: 29566379
[TBL] [Abstract][Full Text] [Related]
16. Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial.
Kalantar-Zadeh K; Schwartz GG; Nicholls SJ; Buhr KA; Ginsberg HN; Johansson JO; Kulikowski E; Lebioda K; Toth PP; Wong N; Sweeney M; Ray KK;
Clin J Am Soc Nephrol; 2021 May; 16(5):705-716. PubMed ID: 33906908
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response
Wasiak S; Gilham D; Daze E; Tsujikawa LM; Halliday C; Stotz SC; Rakai BD; Fu L; Jahagirdar R; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Cardiovasc Ther; 2020; 2020():9397109. PubMed ID: 32821285
[TBL] [Abstract][Full Text] [Related]
18. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
19. RVX 208: A novel BET protein inhibitor, role as an inducer of apo A-I/HDL and beyond.
Ghosh GC; Bhadra R; Ghosh RK; Banerjee K; Gupta A
Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28423226
[TBL] [Abstract][Full Text] [Related]
20. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
